Is a Preoperative Assessment of the Early Recurrence of Pancreatic Cancer Possible after Complete Surgical Resection?
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The prognosis of pancreatic adenocarcinoma (PAC) is poor. The serum carbohydrate antigen 19-9 (CA 19-9) level has been identified as a prognostic indicator of recurrence and reduced overall survival. The aim of this study was to identify preoperative prognostic factors and to create a prognostic model able to assess the early recurrence risk for patients with resectable PAC. Methods: A series of 177 patients with PAC treated surgically at the St. Andrea Hospital of Rome between January 2003 and December 2011 were reviewed retrospectively. Univariate and multivariate analyses were utilized to identify preoperative prognostic indicators. Results: A preoperative CA 19-9 level >228 U/mL, tumor size >3.1 cm, and the presence of pathological preoperative lymph nodes statistically correlated with early recurrence. Together, these three factors predicted the possibility of an early recurrence with 90.4% accuracy. The combination of these three preoperative conditions was identified as an independent parameter for early recurrence based on multivariate analysis (p=0.0314; hazard ratio, 3.9811; 95% confidence interval, 1.1745 to 15.3245). Conclusions: PAC patient candidates for surgical resection should undergo an assessment of early recurrence risk to avoid unnecessary and ineffective resection and to identify patients for whom palliative or alternative treatment may be the treatment of choice.
Abstract
Background/Aims: The prognosis of pancreatic adenocarcinoma (PAC) is poor. The serum carbohydrate antigen 19-9 (CA 19-9) level has been identified as a prognostic indicator of recurrence and reduced overall survival. The aim of this study was to identify preoperative prognostic factors and to create a prognostic model able to assess the early recurrence risk for patients with resectable PAC. Methods: A series of 177 patients with PAC treated surgically at the St. Andrea Hospital of Rome between January 2003 and December 2011 were reviewed retrospectively. Univariate and multivariate analyses were utilized to identify preoperative prognostic indicators. Results: A preoperative CA 19-9 level >228 U/mL, tumor size >3.1 cm, and the presence of pathological preoperative lymph nodes statistically correlated with early recurrence. Together, these three factors predicted the possibility of an early recurrence with 90.4% accuracy. The combination of these three preoperative conditions was identified as an independent parameter for early recurrence based on multivariate analysis (p=0.0314; hazard ratio, 3.9811; 95% confidence interval, 1.1745 to 15.3245). Conclusions: PAC patient candidates for surgical resection should undergo an assessment of early recurrence risk to avoid unnecessary and ineffective resection and to identify patients for whom palliative or alternative treatment may be the treatment of choice.
참고문헌 (21)
- Winter JM, "1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience", J Gastrointest Surg, 10, pp.1199~1210 (2006)
- Hidalgo M., "Pancreatic cancer", N Engl J Med, 362, pp.1605~1617 (2010)
- Kim CB, "Current surgical management of pancreatic cancer", J Gastrointest Oncol, 2, pp.126~135 (2011)
- Brennan MF, "Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas", Ann Surg, 240, pp.293~298 (2004)
- Kim YC, "Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?", J Gastroenterol Hepatol, 24, pp.1869~1875 (2009)
- Hata S, "Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer", Ann Surg Oncol, 19, pp.636~641 (2012)
- La Torre M, "Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma", Am Surg, 78, pp.225~259 (2012)
- La Torre M, "The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma", Ann Surg Oncol, 19, pp.2917~2923 (2012)
- Humphris JL, "The prognostic and predictive value of serum CA19.9 in pancreatic cancer", Ann Oncol, 23, pp.1713~1722 (2012)
- Schlieman MG, "Utility of tumor markers in determining resectability of pancreatic cancer", Arch Surg, 138, pp.951~955 (2003)
- Berger AC, "Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma", Ann Surg Oncol, 11, pp.644~649 (2004)
- Uygur-Bayramicli O, "Type 2 diabetes mellitus and CA 19-9 levels", World J Gastroenterol, 13, pp.5357~5359 (2007)
- Sohn TA, "Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators", J Gastrointest Surg, 4, pp.567~579 (2000)
- La Torre M, "Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis", J Surg Oncol, 104, pp.629~633 (2011)
- Soriano A, "Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography", Am J Gastroenterol, 99, pp.492~501 (2004)
- Varadhachary GR, "Preoperative therapies for resectable and borderline resectable pancreatic cancer", J Gastrointest Oncol, 2, pp.136~142 (2011)
- Fujioka S, "Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma", J Hepatobiliary Pancreat Surg, 14, pp.539~544 (2007)
- La Torre M, "Malnutrition and pancreatic surgery: prevalence and outcomes", J Surg Oncol, 107, pp.702~708 (2013)
- Zhang S, "Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma", World J Gastroenterol, 14, pp.3750~3753 (2008)
- La Torre M, "Post-operative morbidity and mortality in pancreatic surgery. The role of surgical Apgar score", Pancreatology, 13, pp.175~179 (2013)
- Ferrone CR, "Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma", J Clin Oncol, 24, pp.2897~2902 (2006)